



**SZABO  
SCANDIC**

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](http://linkedin.com/company/szaboscandic)



## CYP2A6 Pre-design Chimera RNAi

Catalog # : H00001548-R01 規格 : [ 10 nmol ] [ 20 nmol ]

List All

### Specification

**Product Description:** Homo sapiens cytochrome P450, family 2, subfamily A, polypeptide 6 (CYP2A6), mRNA.

### Application Image

RNAi Knockdown

**Reactivity:** Human

**Supplied Product:** DEPC water

**Target Refseq:** NM\_000762

**Storage Instruction:** Store at -20°C, do not exceed 4 - 5 freeze-thaw cycles to ensure product integrity.

**Note:** Position of the Chimera RNAi.



### Publication Reference

1. dsCheck: highly sensitive off-target search software for double-stranded RNA-mediated RNA interference.  
Naito Y, Yamada T, Matsumiya T, Ui-Tei K, Saigo K, Morishita S. Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W589-91.
2. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect.  
Ui-Tei K, Naito Y, Zenno S, Nishi K, Yamato K, Takahashi F, Juni A, Saigo K. Nucleic Acids Res. 2008 Apr;36(7):2136-51. Epub 2008 Feb 11.
3. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference.  
Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A, Ueda R, Saigo K. Nucleic Acids Res. 2004 Feb 9;32(3):936-48. Print 2004.
4. siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference.  
Naito Y, Yamada T, Ui-Tei K, Morishita S, Saigo K. Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W124-9.

### Applications

#### RNAi Knockdown

#### Gene Information

Entrez GeneID: [1548](#)

Gene Name: CYP2A6

Gene Alias: CPA6,CYP2A,CYP2A3,P450C2A,P450PB

**Gene** cytochrome P450, family 2, subfamily A, polypeptide 6  
**Description:**

**Omim ID:** [122700](#), [122720](#), [188890](#), [211980](#)

**Gene Ontology:** [Hyperlink](#)

**Gene Summary:** This gene, CYP2A6, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to hydroxylate coumarin, and also metabolizes nicotine, aflatoxin B1, nitrosamines, and some pharmaceuticals. Individuals with certain allelic variants are said to have a poor metabolizer phenotype, meaning they do not efficiently metabolize coumarin or nicotine. This gene is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. The gene was formerly referred to as CYP2A3; however, it has been renamed CYP2A6. [provided by RefSeq]

**Other Designations:** coumarin 7-hydroxylase, cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 3, cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6, flavoprotein-linked monooxygenase, xenobiotic monooxygenase

### Gene Pathway

[Caffeine metabolism](#) [Drug metabolism - cytochrome P450](#)  
[Drug metabolism - other enzymes](#) [Metabolic pathways](#) [Retinol metabolism](#)

### Related Disease

[Adenocarcinoma](#) [Attention Deficit Disorder with Hyperactivity](#) [Carcinoma](#). [Hepatocellular Carcinoma](#), [Non-Small-Cell Lung Carcinoma](#), [Small Cell Carcinoma](#), [Squamous Cell Cell Transformation](#), [Neoplastic Cocarcinogenesis](#) [Colorectal Neoplasms](#)  
[Disease Progression](#) [Disease Susceptibility](#) [DNA Damage](#) [Drug Toxicity](#) [Epilepsy](#)  
[Esophageal Neoplasms](#) [Fetal Growth Retardation](#) [Genetic Predisposition to Disease](#)  
[Genetics](#), [Behavioral Genomic Instability](#)

[... see more](#)

[服務條款](#) | [隱私權政策](#) | [著作及商標](#) | [網站地圖](#)

©2016 亞諾法生技股份有限公司 Abnova Corporation. 版權所有.